Asset
VEREKITUG
UPSTREAM BIO INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06966479 | phase2 | active_not_recruiting | 2025-05-21 | 2027-09-01 | Upstream Bio Inc. | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) |
| NCT06981078 | phase2 | active_not_recruiting | 2025-07-02 | 2027-10-01 | Upstream Bio Inc. | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD |
| NCT06196879 | phase2 | completed | 2024-02-27 | 2025-12-16 | Upstream Bio Inc. | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) |
| NCT06164704 | phase2 | completed | 2023-12-18 | 2025-07-07 | Upstream Bio Inc. | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps |
| NCT05448651 | phase1 | completed | 2022-07-08 | 2023-08-15 | Upstream Bio Inc. | Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics |
FDA applications (0)
This company has no applications containing this asset.